Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 31st, there was short interest totalling 1,400 shares, a decline of 60.0% from the May 15th total of 3,500 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 175,800 shares, the short-interest ratio is presently 0.0 days.
Novozymes A/S Trading Down 0.8%
Shares of NVZMY stock traded down $0.58 on Friday, reaching $74.89. 14,670 shares of the stock were exchanged, compared to its average volume of 33,813. The company has a market capitalization of $35.07 billion, a price-to-earnings ratio of 47.40, a PEG ratio of 3.87 and a beta of 0.92. The business's 50 day moving average price is $66.75 and its 200 day moving average price is $60.81. Novozymes A/S has a twelve month low of $53.95 and a twelve month high of $75.88.
Novozymes A/S Company Profile
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Featured Articles
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.